Vitronectin receptor antagonists, their preparation and use

A compound of the formula I,

• A-B-D-E-F-G (I)
• in which:
• A is
• 51
• is a 5-membered to 10-membered monocyclic or polycyclic, aromatic or nonaromatic ring system, which can contain from 1 to 4 heteroatoms from the group N, O and S and can optionally be substituted, once or more than once, by R12, R13, R14 and R15;
• B is a direct linkage, (C1-C8)-alkanediyl, (C5-C10)-arylene, (C3-C8)-cycloalkylene, —C≡C—, —NR2—, —NR2C(O)—, —NR2—C(O)—NR2—, —NR2—C(S)—NR2—, —O—C(O)—, —NR2—S(O)—, —NR2—S(O)2—, —O—, —S— or —CR2═CR3—, which can in each case be substituted, once or twice, by (C1-C8)-alkyl;
• D is a direct linkage, (C1-C8)-alkanediyl, (C5-C10)-arylene, —O—, —NR2—, —CO—NR2—, —NR2—CO—, —NR2—C(O)—NR2—, —NR2—C(S)—NR2—, —OC(O)—, —C(O)O—, —S(O)—, —S(O)2—, —S(O)2—NR2—, —S(O)—NR2—, —NR2—S(O)—, —NR2—S(O)2—, —S—, —CR2═CR3— or —C≡C— which can in each case be substituted, once or twice, by (C1-C8)-alkyl, —CR2═CR3— or (C5-C6)-aryl, with it not being possible for D to be —CO—NR2—, —C(O)O—, —S(O)—, —S(O)2—, —S(O)—NR2— or —S(O)2—NR2— when B is a direct linkage;
• E is a template which is selected from the series of fibrinogen receptor antagonists;
• F is defined like D,
• G is
• 52
• R2 and R3 are, independently of each other, H, (C1-C10)-alkyl, which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C1-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, R8OC(O)R9, R8R8NC(O)R9 or R8C(O)R9;
• R4, R5, R6 and R7 are, independently of each other, H, fluorine, OH, (C1-C8)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl, or R8OR9, R8SR9, R8CO2R9, ROC(O)R9, R8—, C5-C14)-aryl-R9, R8N(R2)R9, R8R8NR9, R8N(R2)C(O)OR9, R8S(O)nN(R2)R9, R8OC(O)N(R2)R9, R8C(O)N(R2)R9, R8N(R2)C(O)N(R2)R9, R8N(R2)S(O)N(R2)R9, R8S(O)nR9, R8SC(O)N(R2)R9, R8C(O)R9, R8N(R2)C(O)R9 or R8N(R2)S(O)nR9;
• R8 is H, (C1-C8)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl or (C5-C14)-aryl-(C1-C8)-alkyl, where the alkyl radicals can be substituted, once or more than once, by fluorine;
• R9 is a direct linkage or (C1-C8)-alkanediyl;
• R10 is C(O)R11, C(S)R11, S(O)R11, P(O)(R11)n or a four-membered to eight-membered, saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the group N, O and S, such as tetrazolyl, imidazolyl, pyrazolyl, oxazolyl or thiadiazolyl;
• R11 is OH, (C1-C8)-alkoxy, (C5-C14)-aryl-(C1-C8)-alkoxy, (C5 C14)-aryloxy, (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkoxy, (C5-C14)-aryl-(C1-C8)-alkylcarbonyloxy-(C1-C6)-alkoxy, NH2, mono- or di-((C1-C8)-alkyl)-amino, (C5-C14)-aryl-(C1-C8)-alkylamino, (C1-C8)-dialkylaminocarbonylmethyloxy (C5-C14)-aryl-(C1-C8)-dialkylaminocarbonylmethyloxy or (C5-C14)-arylamino or the radical of an L-amino acid or D-amino acid;
• R12, R13, R14 and R15 are, independently of each other, H, (C1-C10)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, H2N, R8ONR9, R8OR9, R8OC(O)R9, R8R8NR9, R8—(C5-C14)-aryl-R9, HO(C1-C8)-alkyl-N(R2)R9, R8N(R2)C(O)R9, R8C(O)N(R2)R9, R8C(O)R9, R2R3N—C(═NR2)—NR2, R2R3NC(═NR2), ═O, or ═S;
• where two adjacent substituents from R12 to R15 can also together be —OCH2O— or —OCH2CH2O—;
• Y is NR2, O or S;
• n is 1 or 2;
• p and q are, independently of each other, 0 or 1;
• in all their stereoisomeric forms and mixtures thereof in all proportions, and their physiologically tolerated salts,
• with compounds being excepted in which E
• a) is a 6-membered aromatic ring system which can contain up to 4 N atoms and which can be substituted by from 1 to 4 identical or different arbitrary substituents, or
• b) is 4-methyl-3-oxo-2,3,4,5-tetrahydro-1-H-1,4-benzodiazepine.